首页> 外文OA文献 >Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

【2h】

Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

机译：纠正：GDC-0276的安全性，耐受性和药代动力学，一种新型NAV1.7抑制剂，在健康志愿者中的一体化，单剂量和多剂量研究中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Michael E. Rothenberg; Michael Tagen; Jae H. Chang; Janel Boyce-Rustay; Michel Friesenhahn; David H. Hackos; Avis Hains; Dan Sutherlin; Michael Ward; William Cho;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na(V)1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers (vol 39, pg 873, 2019) [J] . Rothenberg Michael E., Tagen Michael, Chang Jae H., Clinical drug investigation . 2019,第9期

机译：GDC-0276的安全性，耐受性和药代动力学，一种新的NA（v）1.7抑制剂，在健康志愿者的一体化，单剂量和多剂量研究中（Vol 39，PG 873,2019）
2. Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na(V)1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers [J] . Rothenberg Michael E., Tagen Michael, Chang Jae H., Clinical drug investigation . 2019,第9期

机译：GDC-0276的安全性，耐受性和药代动力学，一种新的NA（v）1.7抑制剂，在健康志愿者的一体化，单剂量和多剂量研究中
3. Single- and multiple-dose study to evaluate pharmacokinetics, safety and tolerability in healthy volunteers: A comparison of extended-release oxycodone with sequestered naltrexone 40mg twice daily to oxycontin 40mg twice daily and extended-release oxycodone with sequestered naltrexone 80mg once daily [J] . PfizerInc.NewYork, PfizerInc.Cary, PfizerInc.Groton, Clinical pharmacology in drug development . 2015,第5期

机译：评估健康志愿者的药代动力学，安全性和耐受性的单剂量和多剂量研究：比较：每天两次两次口服纳曲酮的缓释羟考酮与一天两次两次口服羟考酮的40毫克羟考酮和每天一次两次口服纳曲酮的羟考酮连续40毫克的比较
4. Safety, tolerability, pharmacodynamics and pharmacokinetics following single subcutaneous dosesof a teverelix depot formulation in healthy male volunteers [C] . C. MacLean, F. Larsen, R. Piechatzek, Annual meeting exposition of the Controlled Release Society . 2005

机译：在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性，耐受性，药效动力学和药代动力学
5. Pharmacokinetics of artesunate in healthy volunteers. [D] . Naik, Himanshu. 2007

机译：青蒿琥酯在健康志愿者中的药代动力学。
6. Safety Tolerability and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy Volunteers [O] . Barbara J. Brennan, Brian Davies, Georgina Cirrincione-Dall, 2012

机译：静脉输注奥瑟他韦的安全性耐受性和药代动力学：健康志愿者的单剂量和多剂量I期研究
7. Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects [O] . Michael A. Eldon, Edwin L. Parsley, Mari Maurer, 2020

机译：RT234的安全性，耐受性和药代动力学（Vardenafil吸入粉末）：在健康受试者中的一体式，上升的单剂量和多剂量研究

Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

著录项

相似文献

相关主题

期刊订阅